Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun 28;24(24):2537-2554.
doi: 10.3748/wjg.v24.i24.2537.

Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma

Esther Llop  1 , Pedro E Guerrero  1 , Adrià Duran  1 , Sílvia Barrabés  1 , Anna Massaguer  1 , María José Ferri  1 , Maite Albiol-Quer  2 , Rafael de Llorens  1 , Rosa Peracaula  1
Affiliations
Review

Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma

Esther Llop et al. World J Gastroenterol. .

Abstract

Pancreatic cancer (PaC) shows a clear tendency to increase in the next years and therefore represents an important health and social challenge. Currently, there is an important need to find biomarkers for PaC early detection because the existing ones are not useful for that purpose. Recent studies have indicated that there is a large window of time for PaC early detection, which opens the possibility to find early biomarkers that could greatly improve the dismal prognosis of this tumor. The present manuscript reviews the state of the art of the existing PaC biomarkers. It focuses on the anomalous glycosylation process and its role in PaC. Glycan structures of glycoconjugates such as glycoproteins are modified in tumors and these modifications can be detected in biological fluids of the cancer patients. Several studies have found serum glycoproteins with altered glycan chains in PaC patients, but they have not shown enough specificity for PaC. To find more specific cancer glycoproteins we propose to analyze the glycan moieties of a battery of glycoproteins that have been reported to increase in PaC tissues and that can also be found in serum. The combination of these new candidate glycoproteins with their aberrant glycosylation together with the existing biomarkers could result in a panel, which would expect to give better results as a new tool for early diagnosis of PaC and to monitor the disease.

Keywords: Aberrant glycosylation; Biomarkers; Diagnosis; Glycoproteins; Pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare no potential conflicts of interest.

Figures

Figure 1
Figure 1
Overview of pancreatic cancer diagnosis methods: imaging techiques and the exisiting and new potential blood-based biomarkers.
See this image and copyright information in PMC

References

    1. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758–2765. - PubMed
    1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921. - PubMed
    1. Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol. 2017;28:1117–1123. - PubMed
    1. Lucas AL, Malvezzi M, Carioli G, Negri E, La Vecchia C, Boffetta P, Bosetti C. Global Trends in Pancreatic Cancer Mortality From 1980 Through 2013 and Predictions for 2017. Clin Gastroenterol Hepatol. 2016;14:1452–1462.e4. - PMC - PubMed
    1. Brierley JD, Gospodarowicz MK, Wittekind C, editors . UICC. TNM Classification of malignant tumors. 8th ed ; Wiley-Blackwell: Hoboken, NJ, USA; 2017.

MeSH terms